Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 21, 2023 06:00 ET | Source: MediWound Ltd.

MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

YAVNE, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
September 11, 2023 08:00 ET | Source: MediWound Ltd.

MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress

YAVNE, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for...
September 05, 2023 08:00 ET | Source: MediWound Ltd.

MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference

YAVNE, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
August 15, 2023 16:03 ET | Source: MediWound Ltd.

MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update

EscharEx® Phase III study protocol: FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry leaders NexoBrid® U.S. commercial launch timing...
August 15, 2023 16:02 ET | Source: MediWound Ltd.

MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study

YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
August 15, 2023 16:01 ET | Source: MediWound Ltd.

MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study

YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
August 07, 2023 08:00 ET | Source: MediWound Ltd.

MediWound to Report Second Quarter 2023 Financial Results

YAVNE, Israel, Aug. 07, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will...
August 01, 2023 07:30 ET | Source: MediWound Ltd.

MediWound Announces Commercial Launch of NexoBrid® in Japan

YAVNE, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
July 10, 2023 07:30 ET | Source: MediWound Ltd.

MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

MW005 shown to be safe and well-tolerated Data provide clinical efficacy proof-of-concept based on clearance of target lesions YAVNE, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd....
July 03, 2023 07:00 ET | Source: MediWound Ltd.

MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design

YAVNE, Israel, July 03, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...